Q-omics provides the consensus-scored ZNF140 profile across patient tissues and cancer cell-line models. ZNF140 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF140 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ZNF140 RNA expression shows 21,087 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCS, THCA, and KIRP as cancer lineages where ZNF140 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF140 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF140 survival associations across molecular data types. ZNF140 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF140 RNA expression–survival associations across cancer types. High ZNF140 expression shows unfavorable associations in UVM, MESO, LUSC and LGG, but favorable associations in UCS and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF140 RNA expression.
This table summarizes ZNF140 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF140. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF140 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, COAD, CHOL and HNSC. The THCA box plot shows higher ZNF140 RNA expression in normal versus tumor tissue (log2 FC = −0.608, t-test p < 0.001).
This table shows molecular features associated with ZNF140 in patient tissues and cancer cell lines. In patient samples, ZNF140 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF140 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
